Active — Not RecruitingNot Applicable

An Observational Real-world Study Evaluating Severe Tricuspid Regurgitation Patients Treated with the Abbott TriClip™ Device (bRIGHT)

Austria, Denmark, Germany511 participantsStarted 2020-08-27

Plain-language summary

The bRIGHT EU PAS study is an observational real-world study evaluating severe tricuspid regurgitation patients treated with the Abbott TriClip™ device (bRIGHT EU Post-Approval Study).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects (\>=18 years age) have severe tricuspid regurgitation and are symptomatic despite medical therapy.
✓. Subjects eligible to receive the TriClip™ per the current approved Indications for Use.
✓. Subject must provide written informed consent prior to study procedure.

What they're measuring

Acute Procedural Success (APS)

Timeframe: up to 30 days

Trial details

NCT IDNCT04483089

SponsorAbbott Medical Devices

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-12-31

View on ClinicalTrials.gov More Tricuspid Valve Regurgitation trials